Acar C, Partington M T, Buckberg G D
UCLA School of Medicine, Department of Surgery 90024-1741.
J Thorac Cardiovasc Surg. 1991 Feb;101(2):284-93.
Initial reoxygenation with blood cardioplegic solution produces better regional recovery than with Fluosol DA cardioplegic solution (Green Cross Corporation, Osaka, Japan) because blood cardioplegia ensures delivery of important blood components (i.e., plasma and red blood cells) that limit reperfusion damage.
Twenty-five dogs underwent 2 hours of ligation of the left anterior descending coronary artery followed by controlled reperfusion at 50 mm Hg through an internal mammary graft on total vented bypass. Five dogs received normal blood reperfusion, 10 dogs received a 20-minute reperfusion with Fluosol DA 20% cardioplegic solution, and 10 others received a blood cardioplegic reperfusate of identical composition (i.e., pH, calcium, potassium, glucose, osmolarity). Regional oxygen consumption was measured during reperfusion, and segmental shortening (ultrasonic crystals), tissue water content, and histochemical damage (triphenyltetrazolium chloride stain) were assessed 2 hours later.
Reperfusion with normal blood failed to restore contractile function (3% systolic shortening), caused severe edema (81% water content), and caused marked histochemical damage (48% triphenyltetrazolium chloride nonstaining). Hearts reperfused with Fluosol DA cardioplegic solution did not take up as much oxygen as hearts receiving blood cardioplegic reperfusion (37 versus 54 ml/100 gm, p less than 0.05). Blood cardioplegia was superior to Fluosol DA cardioplegia in recovery of segmental contractility (69% versus 34% systolic shortening, p less than 0.05), produced less edema (79.5% versus 80.9% water content, p less than 0.05), and produced less histochemical damage with triphenyltetrazolium chloride (11% versus 40% area of nonstaining/area at risk, p less than 0.05).
Initial reperfusion with a blood cardioplegic solution ensures better oxygen utilization, superior recovery of regional contractility, and less tissue damage than Fluosol DA cardioplegic reperfusion. These data emphasize the importance of including blood components (plasma or red blood cells) in the oxygenated cardioplegic reperfusate to limit reperfusion injury.
与氟碳乳剂DA心脏停搏液(日本大阪绿十字公司)相比,使用含血心脏停搏液进行初始再灌注可产生更好的局部恢复效果,因为含血心脏停搏液可确保输送重要的血液成分(即血浆和红细胞),从而限制再灌注损伤。
25只犬接受2小时左前降支冠状动脉结扎,然后在完全体外循环下通过乳内动脉移植物以50 mmHg进行控制性再灌注。5只犬接受正常血液再灌注,10只犬接受用20%氟碳乳剂DA心脏停搏液进行20分钟的再灌注,另外10只犬接受相同成分(即pH值、钙、钾、葡萄糖、渗透压)的含血心脏停搏液再灌注。在再灌注期间测量局部氧耗,并在2小时后评估节段缩短(超声晶体)、组织含水量和组织化学损伤(氯化三苯基四氮唑染色)。
用正常血液进行再灌注未能恢复收缩功能(收缩期缩短3%),导致严重水肿(含水量81%),并造成明显的组织化学损伤(48%氯化三苯基四氮唑不着色)。用氟碳乳剂DA心脏停搏液再灌注的心脏摄取的氧气不如接受含血心脏停搏液再灌注的心脏多(37对54 ml/100 g,p<0.05)。在节段收缩力恢复方面,含血心脏停搏液优于氟碳乳剂DA心脏停搏液(收缩期缩短69%对34%,p<0.05),产生的水肿较少(含水量79.5%对80.9%,p<0.05),并且用氯化三苯基四氮唑产生的组织化学损伤较少(不着色面积/危险面积11%对40%,p<0.05)。
与氟碳乳剂DA心脏停搏液再灌注相比,使用含血心脏停搏液进行初始再灌注可确保更好的氧利用、更好的局部收缩功能恢复以及更少的组织损伤。这些数据强调了在含氧心脏停搏液再灌注液中加入血液成分(血浆或红细胞)以限制再灌注损伤的重要性。